Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Immunotherapy of cancer

3148 - A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies


10 Oct 2016


Immunotherapy of cancer


Adi Diab


Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378


A. Diab1, A. El-Khoueiry2, F.A. Eskens3, W. Ros4, J.A. Thompson5, C. Konto6, C. Bermingham6, T. Joh7, K. Liao7, B. Ganguly6, O. Hamid8

Author affiliations

  • 1 Cancer Center, MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Clinical Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles/US
  • 3 Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam/NL
  • 4 Molecular Pathology, The Netherlands Cancer Institute, Amsterdam/NL
  • 5 Medical Oncology, University of Washington Seattle Cancer Care Alliance, Seattle/US
  • 6 Global R&d, Rinat-Pfizer, South San Francisco/US
  • 7 Global R&d, Pfizer Inc., La Jolla/US
  • 8 Translational Research And Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles/US


Abstract 3148


Co-stimulation of activated T cells with agonistic monoclonal antibodies (mAb) against the tumor necrosis factor receptor superfamily member OX40 offers a novel immunotherapeutic approach to cancer. OX40 engagement may co-stimulate effector T cells and deplete regulatory T cells, resulting in enhanced tumor immunity. PF-8600 is a fully human agonist IgG2 mAb that targets OX40.


A Phase 1, open label, multicenter study is ongoing to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of PF-8600 in pts with advanced melanoma, head and neck squamous cell, renal cell, or hepatocellular carcinoma. PF-8600 was administered intravenously at increasing doses (0.01 – 3 mg/kg) every 2 weeks until disease progression or unacceptable toxicity. Additional biomarker cohorts (opened at each dose level except 0.01 mg/kg) enrolled pts who consented to baseline and on-treatment tumor biopsies for immune profiling by immunohistochemistry and RNAseq.


As of 09 MAR 2016, 31 pts have enrolled in the dose-escalation phase of PF-8600 study: 0.01 mg/kg (2 pts), 0.1 mg/kg (10 pts), 0.3 mg/kg (8 pts), 1.5 mg/kg (7 pts) and 3 mg/kg (4 pts). 25.8% of patients received ≥ 4 prior therapies for advanced disease. No dose limiting toxicities, no drug-related or immune related grade (G) 3-5 adverse events (AEs) were observed. Drug-related AEs (DRAEs) were all G1/2 events and occurred in 21 pts (67.7%). The most common DRAEs were fatigue (29.0%) and decreased appetite (9.7%). Out of 25 pts evaluable for response, 1 pt experienced partial response (PR, -50%, confirmed), and 15 pts experienced stable disease (SD). 11 pts remain on treatment, and 5 patients continued treatment for >13 weeks. Assessment of peripheral blood lymphocyte indicated full OX40 receptor occupancy at ≥0.3 mg/kg, and maximal memory T cell proliferation at 0.1 and 0.3 mg/kg.


These preliminary results demonstrate that PF-8600 is safe up to 3 mg/kg. Updated safety, antitumor activity, and biomarker data will be presented.

Clinical trial identification


Legal entity responsible for the study

Pfizer, Inc.


Pfizer, Inc.


A. Diab: Advisory board for Nektar Therapeutics. A. El-Khoueiry: Grants:NCI/NIH, CTEP, SWOG Consultant: Genentech, Bayer, Astra-Zeneca, Medimmune, Celgene, BMS, Transgene Speakers Bureau: Merrimack Contracted. Research: Pfizer,CeloNova, Novartis, AstraZeneca, BMS, Genentech, Pfizer, Astex, Daiichi Sankyo, Nektar, Exelixis, Chiltern. F.A. Eskens: Adboard for Baxalta, Merck, AMGEN. C. Konto: Pfizer's employee and shareholder. C. Bermingham: I have Pfizer stock as part of my 401K. T. Joh: I am Pfizer employee, and stock owner. K. Liao: Currently, I am employed by Pfizer Inc. and own Pfizer stock. B. Ganguly: I am a Pfizer employee and that I own Pfizer stock. O. Hamid: Consulting: Amgen, Novartis, Roche, BMS. Speaker: Amgen, BMS, Genentech, Merck, Novartis. Contracted Research: Astra Zeneca, BMS, Celldex, Genentech, Immunocore, Incyte, Merck, Merck-Serano, MedImmune, Novartis, Pfizer, Rinat, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings